<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Since the association between <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> and <z:e sem="disease" ids="C0039128" disease_type="Disease or Syndrome" abbrv="">syphilis</z:e> was first described, many other <z:mp ids='MP_0001799'>viral</z:mp>, <z:mp ids='MP_0001794'>bacterial</z:mp> and <z:e sem="disease" ids="C0747256" disease_type="Disease or Syndrome" abbrv="">parasitic infections</z:e> have been shown to induce <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo>, notably anticardiolipin antibodies </plain></SENT>
<SENT sid="1" pm="."><plain>These aPL are usually associated neither with anti-beta2 <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I antibodies (anti-beta2-GPI) nor with thrombotic events, even if cases of arterial and <z:hpo ids='HP_0002625'>deep venous thrombosis</z:hpo> have been reported in such circumstances </plain></SENT>
<SENT sid="2" pm="."><plain>A literature review shows that anticardiolipin antibodies occur frequently in <z:mp ids='MP_0001799'>viral</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>, particularly in HIV (49.8%), HBV (24%) and HCV (20%) </plain></SENT>
<SENT sid="3" pm="."><plain>The prevalence of anti-beta2 <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I antibodies (anti-beta2GPI) is lower (HCV: 1.7%, HIV: 5.6%, HBV: 3.3%) and there is no demonstrated association with a risk of thrombotic events or hematological manifestations defining <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) </plain></SENT>
<SENT sid="4" pm="."><plain>Regarding other <z:mp ids='MP_0001799'>viral</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>, including <z:hpo ids='HP_0006562'>viral hepatitis</z:hpo> A, <z:e sem="disease" ids="C0019340" disease_type="Disease or Syndrome" abbrv="">herpes</z:e> virus (CMV, EBV, VZV), parvovirus B19 and <z:e sem="disease" ids="C1512326" disease_type="Disease or Syndrome" abbrv="">HTLV-1 infections</z:e>, only a few studies are available but data confirm the high prevalence of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> at the <z:hpo ids='HP_0011009'>acute</z:hpo> phase </plain></SENT>
<SENT sid="5" pm="."><plain>Finally, <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo>, mainly anticardiolipin, are frequently associated with <z:mp ids='MP_0001799'>viral</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Their presence may probably reflect an intense or <z:hpo ids='HP_0011010'>chronic</z:hpo> antigenic stimulation of the immune system </plain></SENT>
<SENT sid="7" pm="."><plain>However, their evolution under antiviral therapy and correlation with the quality of the virological control and/or the immune restoration remain to be determined </plain></SENT>
</text></document>